The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With ≥200 Units Per Day of U-500 Insulin
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms I-CAN
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2017 Status changed from suspended to withdrawn prior to enrolment.
- 22 Feb 2016 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.